HK1010050A1 - The sulphate salt of a substituted triazole pharmaceutical compositions thereof and their use in therapy - Google Patents

The sulphate salt of a substituted triazole pharmaceutical compositions thereof and their use in therapy

Info

Publication number
HK1010050A1
HK1010050A1 HK98110478A HK98110478A HK1010050A1 HK 1010050 A1 HK1010050 A1 HK 1010050A1 HK 98110478 A HK98110478 A HK 98110478A HK 98110478 A HK98110478 A HK 98110478A HK 1010050 A1 HK1010050 A1 HK 1010050A1
Authority
HK
Hong Kong
Prior art keywords
therapy
pharmaceutical compositions
sulphate salt
substituted triazole
receptors
Prior art date
Application number
HK98110478A
Other languages
English (en)
Inventor
Raymond Baker
Kendal G Pitt
Victor G Matassa
Carole Olive
David E Storey
Leslie J Street
Alexander Richard Guiblin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211903A external-priority patent/GB9211903D0/en
Priority claimed from GB939307306A external-priority patent/GB9307306D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HK1010050A1 publication Critical patent/HK1010050A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
HK98110478A 1992-06-05 1998-09-05 The sulphate salt of a substituted triazole pharmaceutical compositions thereof and their use in therapy HK1010050A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211903A GB9211903D0 (en) 1992-06-05 1992-06-05 Pharmaceutical composition
GB939307306A GB9307306D0 (en) 1993-04-07 1993-04-07 Therapeutic agents

Publications (1)

Publication Number Publication Date
HK1010050A1 true HK1010050A1 (en) 1999-06-11

Family

ID=26301005

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110478A HK1010050A1 (en) 1992-06-05 1998-09-05 The sulphate salt of a substituted triazole pharmaceutical compositions thereof and their use in therapy

Country Status (27)

Country Link
US (1) US5527817A (bg)
EP (1) EP0573221B1 (bg)
JP (2) JP2619197B2 (bg)
KR (1) KR100286411B1 (bg)
CN (1) CN1043532C (bg)
AT (1) ATE165602T1 (bg)
AU (2) AU659311B2 (bg)
BG (1) BG61976B1 (bg)
CA (1) CA2097208C (bg)
CZ (1) CZ282060B6 (bg)
DE (1) DE69318212T2 (bg)
DK (1) DK0573221T3 (bg)
ES (1) ES2116411T3 (bg)
FI (3) FI106201B (bg)
HK (1) HK1010050A1 (bg)
HU (1) HUT71403A (bg)
IL (1) IL105847A (bg)
LV (1) LV12210B (bg)
MX (1) MX9303373A (bg)
NO (1) NO307420B1 (bg)
NZ (1) NZ253210A (bg)
RO (1) RO114326B1 (bg)
RU (1) RU2130022C1 (bg)
SG (1) SG50406A1 (bg)
SK (1) SK279211B6 (bg)
UA (1) UA27908C2 (bg)
WO (1) WO1993025547A1 (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1997003068A1 (en) * 1995-07-11 1997-01-30 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
CA2455050C (en) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
EP1951713A1 (en) * 2005-11-14 2008-08-06 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
EP2160390A1 (en) * 2007-06-04 2010-03-10 Generics Ýuk¨Limited Novel process
EP3407869A1 (en) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2024144413A1 (ru) * 2022-12-28 2024-07-04 Общество С Ограниченной Ответственностью "Ферринг Продакшн" Жидкая фармацевтическая композиция для назального введения, содержащая ризатриптан

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi

Also Published As

Publication number Publication date
AU659311B2 (en) 1995-05-11
HUT71403A (en) 1995-11-28
NO307420B1 (no) 2000-04-03
CN1089263A (zh) 1994-07-13
IL105847A0 (en) 1993-09-22
FI20001777A (fi) 2000-08-10
WO1993025547A1 (en) 1993-12-23
JPH0641121A (ja) 1994-02-15
DK0573221T3 (da) 1998-10-07
SG50406A1 (en) 1998-07-20
DE69318212T2 (de) 1998-11-19
US5527817A (en) 1996-06-18
LV12210A (lv) 1999-01-20
FI106201B (fi) 2000-12-15
SK147994A3 (en) 1995-07-11
KR100286411B1 (ko) 2001-04-16
BG99132A (bg) 1995-07-28
FI945694A0 (fi) 1994-12-02
CZ282060B6 (cs) 1997-05-14
RO114326B1 (ro) 1999-03-30
FI20001776A (fi) 2000-08-10
AU4337293A (en) 1994-01-04
BG61976B1 (bg) 1998-11-30
CZ304494A3 (en) 1995-09-13
IL105847A (en) 1998-09-24
CN1043532C (zh) 1999-06-02
RU94046380A (ru) 1996-12-10
SK279211B6 (sk) 1998-08-05
LV12210B (en) 1999-03-20
JP2972150B2 (ja) 1999-11-08
CA2097208C (en) 2005-02-08
JPH09176155A (ja) 1997-07-08
NZ253210A (en) 1995-09-26
EP0573221B1 (en) 1998-04-29
HU9403478D0 (en) 1995-02-28
UA27908C2 (uk) 2000-10-16
JP2619197B2 (ja) 1997-06-11
NO944656D0 (no) 1994-12-02
KR950701922A (ko) 1995-05-17
NO944656L (no) 1994-12-02
RU2130022C1 (ru) 1999-05-10
FI945694A (fi) 1994-12-02
ES2116411T3 (es) 1998-07-16
EP0573221A1 (en) 1993-12-08
MX9303373A (es) 1995-01-31
ATE165602T1 (de) 1998-05-15
AU3987593A (en) 1993-12-09
CA2097208A1 (en) 1993-12-06
DE69318212D1 (de) 1998-06-04

Similar Documents

Publication Publication Date Title
IL96891A0 (en) Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
HU9403478D0 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
AU4215593A (en) 4-substituted 1,2,4-triazole derivatives
HU9202231D0 (en) Fungicidal preparative of synergetic effect
ITRM950480A0 (it) Metodo per aumentare la rapidita' di allevamento di neonati mediante impiego di mangime per scrofe da riproduzione.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
GB9207396D0 (en) Therapeutic agents
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
MY110795A (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
ITRM940322A0 (it) "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
DE3473447D1 (en) Triazole antifungal agents
AU6542896A (en) A triazolylmethyl-indole ethylamine bisulfate salt
MY108739A (en) Imidazole, triazole and tetrazole derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)